BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF), an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies.
Research on AstraZeneca PLC (LSE:AZN) by JP Morgan underlined the scale of the opportunity on offer for the micro-cap life sciences companies developing the.
BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) has added two potential cancer therapies to its pipeline - BVX002 and BVX003. They join BVX001, a putative.
BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) s Chief executive Tiffany Thorn talks to Proactive London about their method and adding two potential cancer.
BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) is looking to strengthen its intellectual property base with four UK patent applications related to several.